Bioscore was adopted in breast cancer incorporating the staging system and several biologic factors done on 3,728 patients treated with surgery between 1997 and 2006; these factors include grade and estrogen receptor status and proved to be more impactful in determining (disease specific survival) DSS [30]. This evidence concerns the gene ESR1 and breast carcinoma.